Intravitreal administration of bevacizumab: pros and cons.
作者信息
Dashti-Khavidaki Simin, Abdollahi Mohammad
机构信息
Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, 1417614411, Iran.
出版信息
Daru. 2015 Apr 21;23(1):27. doi: 10.1186/s40199-015-0110-0.
Abstract
摘要
相似文献
1
Intravitreal administration of bevacizumab: pros and cons.玻璃体腔内注射贝伐单抗：利弊
Daru. 2015 Apr 21;23(1):27. doi: 10.1186/s40199-015-0110-0.
2
Bevacizumab for Intravitreal Injection: Impact of Sub-Visible Particles on the Shelf-Life of Repackaged Bevacizumab.贝伐珠单抗玻璃体腔内注射：亚可见颗粒对重新包装的贝伐珠单抗货架期的影响。
J Ocul Pharmacol Ther. 2019 Jul/Aug;35(6):372-375. doi: 10.1089/jop.2019.0042. Epub 2019 Jun 28.
3
Effect of Regulatory Requirement for Patient-Specific Prescriptions for Off-Label Medications on the Use of Intravitreal Bevacizumab.针对非标签用药的患者特定处方的监管要求对玻璃体内注射贝伐单抗使用情况的影响。
JAMA Ophthalmol. 2016 Jan;134(1):45-8. doi: 10.1001/jamaophthalmol.2015.4331.
4
Silicone oil droplets after intravitreal bevacizumab injection in two patients.
Arch Soc Esp Oftalmol (Engl Ed). 2020 Jun;95(6):e43. doi: 10.1016/j.oftal.2020.03.016. Epub 2020 May 4.
5
[Extemporaneous withdrawal with a mini-spike filter: A low infection risk technique for drawing up bevacizumab for intravitreal injection].[使用微型尖峰过滤器进行即时抽取：一种用于抽取玻璃体内注射用贝伐单抗的低感染风险技术]
J Fr Ophtalmol. 2016 May;39(5):415-20. doi: 10.1016/j.jfo.2016.01.007. Epub 2016 May 5.
6
[Imaging of choroidal neovascularization associated with Best's disease treated by intravitreal Bevacizumab].玻璃体内注射贝伐单抗治疗Best病相关脉络膜新生血管的影像学研究
J Fr Ophtalmol. 2019 Jun;42(6):e241-e244. doi: 10.1016/j.jfo.2018.11.023. Epub 2019 May 9.
7
[Intravitreal bevacizumab in the treatment of idiopathic juxtafoveal telangiectasis type I].
Arch Soc Esp Oftalmol. 2014 Jul;89(7):269-71. doi: 10.1016/j.oftal.2013.01.006. Epub 2013 Apr 10.
8
Effect of treatment of rectal cancer metastasis with intravitreal bevacizumab (Avastin) in patient with subretinal fluid and macular oedema: short-term follow-up.玻璃体腔内注射贝伐单抗（阿瓦斯汀）治疗视网膜下液和黄斑水肿的直肠癌转移患者的疗效：短期随访
BMJ Case Rep. 2016 Sep 2;2016:bcr2016216273. doi: 10.1136/bcr-2016-216273.
9
Compounding bevacizumab for intravitreal injection: does USP <797> always apply?配制用于玻璃体内注射的贝伐单抗：《美国药典》<797>是否始终适用？
Retina. 2013 Oct;33(9):1733-4. doi: 10.1097/IAE.0b013e31829f742c.
10
REPORT OF SAFETY OF THE USE OF A SHORT 32G NEEDLE FOR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINOPATHY OF PREMATURITY: A Multicenter Study.用于早产儿视网膜病变玻璃体腔内抗血管内皮生长因子注射的32G短针使用安全性报告：一项多中心研究
Retina. 2018 Jun;38(6):1251-1255. doi: 10.1097/IAE.0000000000002172.
引用本文的文献
1
Rapidly dissolving bilayer microneedles enabling minimally invasive and efficient protein delivery to the posterior segment of the eye.快速溶解双层微针，实现微创、高效的蛋白质递送至眼部后节。
Drug Deliv Transl Res. 2023 Aug;13(8):2142-2158. doi: 10.1007/s13346-022-01190-x. Epub 2022 Jun 17.
本文引用的文献
1
Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial.使用单剂量瓶多次玻璃体内注射贝伐单抗后发生的眼内炎群集。
Indian J Ophthalmol. 2016 Sep;64(9):694-696. doi: 10.4103/0301-4738.99855.
2
After counterfeit Avastin®--what have we learned and what can be done?假冒贝伐珠单抗（阿瓦斯汀）事件之后：我们了解了什么？可以做些什么？
Nat Rev Clin Oncol. 2015 May;12(5):302-8. doi: 10.1038/nrclinonc.2015.35. Epub 2015 Mar 3.
3
Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).年龄相关性黄斑变性治疗试验（CATT）中的注射后眼内炎
Ophthalmology. 2015 Apr;122(4):817-21. doi: 10.1016/j.ophtha.2014.10.027. Epub 2015 Jan 15.
4
Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.贝伐单抗用于治疗年龄相关性黄斑变性和病理性近视继发的脉络膜新生血管。
Expert Opin Biol Ther. 2014 Dec;14(12):1837-48. doi: 10.1517/14712598.2014.967210. Epub 2014 Oct 4.
5
Evaluation of compounded bevacizumab prepared for intravitreal injection.评估用于玻璃体内注射的复方贝伐单抗。
JAMA Ophthalmol. 2015 Jan;133(1):32-9. doi: 10.1001/jamaophthalmol.2014.3591.
6
The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review.玻璃体内注射贝伐单抗单药治疗成人眼科疾病的安全性：系统评价
BMJ Open. 2014 Jul 17;4(7):e005244. doi: 10.1136/bmjopen-2014-005244.
7
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.雷珠单抗与贝伐单抗治疗新生血管性年龄相关性黄斑变性的比较：来自 GEFAL 非劣效性随机试验的结果。
Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.
8
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.抑制年龄相关性脉络膜新生血管中 VEGF 的替代治疗：IVAN 随机对照试验的 2 年发现。
Lancet. 2013 Oct 12;382(9900):1258-67. doi: 10.1016/S0140-6736(13)61501-9. Epub 2013 Jul 19.
9
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.抗血管内皮生长因子药物玻璃体内注射相关的不良反应和并发症：文献复习。
Eye (Lond). 2013 Jul;27(7):787-94. doi: 10.1038/eye.2013.107. Epub 2013 May 31.
10
Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center.单中心玻璃体腔注射贝伐单抗后急性眼内炎的发生率。
Retina. 2013 May;33(5):971-4. doi: 10.1097/IAE.0b013e31826f0675.
Zotero 插件